TITLE

Additional Isights Into Pergolide-Associated Valvular Heart Disease

AUTHOR(S)
Lanier, William L.
PUB. DATE
June 2003
SOURCE
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p684
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Editorial. Focuses on pergolide-associated valvular heart disease (PAVHD). Risk of PAVHD, according to the drug company Eli Lilly & Co.; Collaboration between the 'Mayo Clinic Proceedings' and U.S. Food and Drug Administration; Possible errors in assessing the incidence of PAVHD.
ACCESSION #
10544689

 

Related Articles

  • Mixing diet drugs calls for caution.  // FDA Consumer;Sep/Oct97, Vol. 31 Issue 6, p3 

    Scrutinizes US Food and Drug Administration's advise on doctors to monitor heart valve disease in women on taking obesity drugs, fenfluramine and phentermine, as therapy. Indications of the drugs; Responsibilities of health professionals in giving the therapy to the patients.

  • Cardiac valvulopathy associated with exposure to... Bowen, R.; Glicklich, A. // MMWR: Morbidity & Mortality Weekly Report;11/14/1997, Vol. 46 Issue 45, p1061 

    Reports the summary of data gathered by the US Food and Drug Administration (FDA) about the increased cases of fenfluramine or dexfenfluramine-associated valvulopathy. Decision to request voluntary withdrawal of these drugs from the market; Interim public health recommendations for persons...

  • The US Food and Drug Administration's Registry of Patients With Pergolide-Associated Valvular Heart Disease. Flowers, Charlene M.; Racoosin, Judith A.; Lu, Susan L.; Beitz, Julie G. // Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p730 

    Discusses the U.S. Food and Drug Administration's (FDA) registry of patients with pergolide-associated valvular heart disease. Summary of 12 cases in the FDA database; Comparison with three cases reported in the 'Mayo Clinic Proceedings'; Association between fibrotic changes and ergot derivatives.

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // OB/GYN Clinical Alert;May2007, Vol. 24 Issue 1, Special section p2 

    The article reports on the decision of the U.S. Food and Drug Administration to withdraw Pergolide from the market after reports of serious valvular heart disease associated with the drug. The move was prompted by two reports published in the January 4, 2007 issue of the "New England Journal of...

  • Pergolide Off the Market, Heart Disease Risk. Elliott, William T. // Clinical Oncology Alert;May2007, Vol. 23 Issue 5, p2 

    The article reports that pergolide is being withdrawn from the market by the U.S. Food and Drug Administration (FDA) after reports of valvular heart disease associated with the drug. The action of the FDA was prompted by reports published in the January 4, 2007 issue of the "New England Journal...

  • Myocor study in 'new frontier' of percutaneous valve repair. Ford, Omar // Medical Device Daily;12/7/2007, Vol. 11 Issue 222, p1 

    The article reports on the plan of medical technology start-up Myocor to conduct research on percutaneous valve repair. The U.S. Food and Drug Authority (FDA) granted conditional approval to the company's Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) feasibility study. The...

  • FDA approves first catheter-based artificial heart valve in the U.S. PEDERSEN, AMANDA // Medical Device Daily;11/4/2011, Vol. 15 Issue 212, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to the transfemoral delivery of the Sapien catheter-based artificial heart valve from Edwards Lifesciences. An overview of the transcatheter aortic valve replacement (TAVR) procedure for aortic valve...

  • FDA gives expanded indication for Edwards' Sapien valve.  // Medical Device Daily;10/22/2012, Vol. 16 Issue 204, p3 

    The article reports on the U.S. Food and Drug Administration (FDA) approval received by Edwards Lifesciences for its Edwards Sapien transcatheter aortic heart valve. The device is delivered both transfemorally and transapically. The device is intended for treating patients with severe...

  • Drug for Parkinson's Disease Linked to Heart Valve Damage.  // Nutrition Health Review: The Consumer's Medical Journal;2006, Issue 97, p5 

    The article focuses on the cardiovascular risks associated with the drug Permax®, manufactured by Eli Lilly & Co. It reports that the drug is a dopamine agonist and is used in the treatment of Parkinson's disease (PD). It mentions several studies showing an association between the drug and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics